GSK3B and bipolar disorder: Further, it is in agreement with the treatment efficacy of lithium targeting the circadian clock regulator glycogen synthase kinase 3β (GSK3β) [4], with findings of low melatonin levels in patients with bipolar and depressive disorder [15], and with increased melatonin suppression by light in bipolar disorder patients [16].